Nitta Gelatin India Ltd

Nitta Gelatin India Ltd

₹ 1,283 -0.35%
12 May - close price
About

Incorporated in 1975, Nitta Gelatin India Ltd manufactures and sells ossein, gelatin, and collagen peptide[1]

Key Points

Business Overview:[1]
NGIL, a joint venture between the Kerala State Industrial Development Corporation (32% shareholding) and Osaka-based NGI (43% stake), manufactures gelatin, ossein, limed ossein, and DCP from processed animal bones. It also produces collagen peptide-based consumer products for the pharmaceutical and healthcare industries.

  • Market Cap 1,159 Cr.
  • Current Price 1,283
  • High / Low 1,351 / 742
  • Stock P/E 11.8
  • Book Value 563
  • Dividend Yield 0.47 %
  • ROCE 27.4 %
  • ROE 21.1 %
  • Face Value 10.0

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • The company has delivered a poor sales growth of 8.22% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
146 128 140 134 130 130 132 135 129 139 138 150 162
119 90 108 102 110 102 107 107 106 111 112 112 116
Operating Profit 27 39 31 32 20 29 26 27 23 27 26 38 45
OPM % 18% 30% 22% 24% 15% 22% 20% 20% 18% 20% 19% 25% 28%
0 3 3 0 5 1 4 9 6 2 3 1 5
Interest 0 0 0 0 2 0 0 0 0 0 0 0 0
Depreciation 4 4 4 4 4 3 3 3 3 3 4 4 4
Profit before tax 23 38 30 29 20 27 27 33 26 26 25 35 46
Tax % 27% 25% 27% 28% 33% 26% 24% 25% 24% 26% 27% 27% 26%
17 28 22 21 13 20 20 24 20 19 18 26 34
EPS in Rs 17.82 30.32 23.45 21.90 15.36 21.65 22.26 26.92 21.62 21.11 20.30 28.16 37.54
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
354 357 356 342 303 342 396 506 565 533 533 588
330 321 320 313 273 306 351 442 452 409 428 452
Operating Profit 24 36 36 29 30 36 45 64 114 124 105 136
OPM % 7% 10% 10% 8% 10% 10% 11% 13% 20% 23% 20% 23%
2 2 9 5 1 2 1 5 4 11 23 12
Interest 10 8 7 7 9 8 6 5 4 3 2 1
Depreciation 14 13 14 15 15 16 16 14 14 15 14 15
Profit before tax 1 18 24 12 7 13 25 49 99 116 112 132
Tax % 358% 53% 49% 61% 33% 8% 29% 29% 25% 28% 25% 26%
-4 9 12 5 5 12 18 35 74 84 84 97
EPS in Rs -1.56 11.82 15.61 4.90 3.82 12.38 19.15 36.26 77.44 91.02 92.45 107.10
Dividend Payout % -64% 21% 16% 51% 39% 20% 16% 11% 10% 7% 9% 7%
Compounded Sales Growth
10 Years: 5%
5 Years: 8%
3 Years: 1%
TTM: 10%
Compounded Profit Growth
10 Years: 25%
5 Years: 41%
3 Years: 13%
TTM: 31%
Stock Price CAGR
10 Years: 21%
5 Years: 48%
3 Years: 16%
1 Year: 68%
Return on Equity
10 Years: 18%
5 Years: 23%
3 Years: 22%
Last Year: 21%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 9 9 9 9 9 9 9 9 9 9 9 9
Reserves 99 105 124 139 141 144 164 192 259 334 413 502
66 92 109 104 108 84 80 86 39 14 31 4
49 50 59 54 55 57 53 58 60 65 62 71
Total Liabilities 223 256 301 306 313 294 306 345 367 423 515 586
118 120 110 113 130 121 113 107 114 114 117 149
CWIP 9 9 13 10 4 4 2 7 7 8 19 14
Investments 1 1 1 1 1 1 1 1 1 1 7 8
96 127 177 182 179 169 191 230 246 300 372 415
Total Assets 223 256 301 306 313 294 306 345 367 423 515 586

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
20 20 11 27 22 40 19 17 101 94 75 122
-8 -14 -3 -7 -14 -10 -7 -14 -18 -54 -9 -182
-12 18 -5 -20 -7 -33 -12 -2 -55 -36 11 -37
Net Cash Flow 0 25 3 -0 1 -3 -0 1 28 4 77 -97
Free Cash Flow 12 6 -7 12 5 30 11 2 82 78 52 72
CFO/OP 99% 73% 54% 133% 93% 124% 54% 33% 112% 102% 96% 114%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 23 21 54 66 76 37 58 64 57 58 65 61
Inventory Days 100 114 144 153 191 205 161 136 126 156 136 120
Days Payable 51 42 48 53 59 49 43 28 39 44 39 54
Cash Conversion Cycle 72 93 150 165 209 193 176 172 144 170 162 127
Working Capital Days 10 17 31 31 26 27 55 55 70 90 83 94
ROCE % 6% 13% 14% 7% 6% 9% 12% 20% 33% 35% 25% 27%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Export Share of Gelatin Sales
% ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Production Volume - Di-Calcium Phosphate (DCP) (Subsidiaries)
MT
Production Volume - Ossein (Subsidiaries)
MT
Export Share of Collagen Peptide Sales
% ・Standalone data
Installed Capacity - Gelatin
MT per year ・Standalone data
Gelatin Capacity Expansion Announced
MT ・Standalone data
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
74.49% 74.49% 74.49% 74.49% 74.49% 74.49% 74.49% 74.49% 74.49% 74.49% 74.49% 74.49%
0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
0.26% 0.12% 0.12% 0.12% 0.12% 0.12% 0.08% 0.09% 0.35% 0.64% 0.75% 0.93%
25.26% 25.41% 25.40% 25.40% 25.39% 25.40% 25.45% 25.43% 25.17% 24.89% 24.76% 24.59%
No. of Shareholders 8,46610,18311,02811,57311,78312,22912,23912,07811,57411,24810,88110,551

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents